In a report released yesterday, Patrick Walravens from JMP Securities maintained a Buy rating on WalkMe (WKME – Research Report), with a price target of $28.00. The company’s shares closed yesterday at $12.26.
Walravens covers the Technology sector, focusing on stocks such as WalkMe, SAP AG, and MongoDB. According to TipRanks, Walravens has an average return of 10.4% and a 53.20% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for WalkMe with a $16.75 average price target, representing a 36.62% upside. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $20.00 price target.
Based on WalkMe’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $56.85 million and a GAAP net loss of $23.03 million. In comparison, last year the company earned a revenue of $42.65 million and had a GAAP net loss of $23.97 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
WalkMe Ltd is the defining solution enabling organizations to better realize the value of software investments. It is a cloud-based digital adoption platform, users employees and customers of organizations can navigate websites, SaaS applications, and mobile apps through a digital, GPS-like experience to accomplish any task from simple, online transactions, to complex cross-application software processes, to fully autonomous experiences that require no manual clicks or entries.
Read More on WKME:
- Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
- Desjardins Reaffirms Their Buy Rating on Canadian Tire (CDNAF)
- Apyx Medical (APYX) Receives a Buy from JMP Securities
- Analysts Are Bullish on These Healthcare Stocks: Aura Biosciences Inc (AURA), Spectrum Pharmaceuticals (SPPI)
- JMP Securities Remains a Buy on Larimar Therapeutics (LRMR)